title: Ivabradine for the prevention of inappropriate shocks due to sinus tachycardia in patients with an implanted cardioverter defibrillator.
abstract: OBJECTIVE
  Ivabradine is a specific blocker of the pacemaker current (I(f)) used to decrease the sinus rate. Several clinical trials have shown that it is beneficial, with or without concomitant beta-blocker therapy, in patients with stable angina or heart failure. We sought to take advantage of ivabradine's ability to decrease the maximal obtainable sinus rate in order to prevent inappropriate shocks due to sinus tachycardia in patients with an implanted cardioverter defibrillator (ICD).
  
  
  RESULTS
  Prospective open-label series including all our patients with an implanted ICD who, during the course of 2010-2011, received ivabradine with the only purpose of preventing inappropriate ICD shocks for sinus tachycardia. These are patients who received one or more inappropriate shocks for sinus tachycardia or were conceived to be at very high risk for developing such complication. Our series includes five patients who received ivabradine (5-10 mg/day) in addition to their usual beta-blocker therapy. During a follow-up of 14 months no inappropriate shocks due to sinus tachycardia were recorded.
  
  
  CONCLUSIONS
  It is sensible to recommend ivabradine for the prevention of inappropriate ICD shocks due to sinus tachycardia in carefully selected patients.
authors.affiliation: Department of Cardiology,  Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Weizman 6, Tel Aviv 64239,  Israel.
authors.forename: Arnon
authors.initials: A
authors.lastname: Adler
authors.forename: Raphael
authors.initials: R
authors.lastname: Rosso
authors.forename: Ilana
authors.initials: I
authors.lastname: Meir
authors.forename: Sami
authors.initials: S
authors.lastname: Viskin
mesh_terms: D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use*; D017147:Defibrillators, Implantable; D004554:Electric Countershock / Q000009:adverse effects / Q000295:instrumentation*; D004562:Electrocardiography; D004867:Equipment Design; D004868:Equipment Failure; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D000077550:Ivabradine; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011446:Prospective Studies; D013616:Tachycardia, Sinus / Q000503:physiopathology / Q000517:prevention & control*; D017180:Tachycardia, Ventricular / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D001552:Benzazepines; D000077550:Ivabradine